Trials / Unknown
UnknownNCT04486092
Mood Stabilizer-induced Metabolic Abnormalities in Bipolar Disorder
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- National Cheng-Kung University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The potential effects of microbiota in bipolar disorder (BD) with microbiota-related dysfunction have not yet been explored clinically, and the integration of microbiota and pharmacometabolomic approaches can provide us the identification of the significant effects of mood stabilizers on metabolic homeostasis, treatment response, and cognitive performance. Therefore, we propose to develop the integration of the microbiota and pharmacometabolomics knowledge base about the mood stabilizer-induced metabolic abnormalities in BD patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valproic Acid |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2021-07-01
- Completion
- 2021-07-01
- First posted
- 2020-07-24
- Last updated
- 2020-07-24
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04486092. Inclusion in this directory is not an endorsement.